OBI Pharma transfers exclusive rights to develop, commercialize Dificid (fidaxomicin)
OBI Pharma, Inc. today announced an agreement with MSD, known as Merck in the United States and Canada, through a subsidiary transferring exclusive rights to develop and commercialize Dificid (fidaxomicin) in Taiwan to MSD.